Skip to main content

Table 1 Baseline and microbiological characteristics of patients

From: A phase 1 trial of nebulised heparin in acute lung injury

Variable

Dose

Combined n (%)

 

50,000 U/day

100,000 U/day

200,000 U/day

400,000 U/day

 

Number of patients

4

4

4

4

16

Age (years)

57.7 ± 17.3

61.3 ± 14.2

54.3 ± 17.6

60.0 ± 13.0

58.3 ± 14.3

Male

2

1

4

1

8 (50)

Acute Physiological and Chronic Health Evaluation II score

22.3 ± 6.0

21.8 ± 8.7

18.3 ± 10

20.0 ± 3.4

20.6 ± 7.0

Subcutaneous heparin

4

3

4

3

14 (88)

Arterial to inspired oxygen ratio (mmHg)

159 ± 37

143 ± 48

207 ± 79

226 ± 75

183 ± 66

Lung compliance (ml/cmH2O)

30 ± 7

19 ± 5

37 ± 21

22 ± 14

26 ± 14

Alveolar dead space fraction

0.15 ± 0.04

0.3 ± 0.10

0.17 ± 0.07

0.24 ± 0.1

0.23 ± 0.1

Creatinine (μmol/l)

80 ± 45

56 ± 14

130 ± 154

97 ± 45

91 ± 80

Activated partial thromboplastin time (s)

38 ± 7

37 ± 6

44 ± 7

47 ± 20

41 ± 11

Thrombin clotting time (s)

17 ± 2

21 ± 3

20 ± 10

19 ± 3

19 ± 5

Acute lung injury cause

     

   Pneumonia

3

3

2

2

10 (63)

   Sepsis

0

0

1

1

2 (13)

   Pancreatitis

0

1

0

1

2 (13)

   Empyema

1

0

1

0

2 (13)

   Aspiration

0

0

0

0

0

Surgical admission

3

0

1

2

6 (38)

Microbiology

     

   Gram-negative

1

0

2

1

4 (25)

   Gram-positive

1

2

1

0

4 (25)

   Other

0

1

0

2

3 (19)

   No pathogen detected

2

1

1

1

5 (31)

Blood culture-positive

0

0

1

1

2 (12)